The Zacks Analyst Blog Highlights: Accenture, Huron Consulting, CBIZ, CRA International And CoreLogic

For Immediate Release

Chicago, IL – September 30, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Accenture (NYSE:ACN) , Huron Consulting Group Inc. (NASDAQ:HURN) , CBIZ, Inc. (NYSE:CBZ) , CRA International, Inc. (NASDAQ:CRAI) and CoreLogic, Inc. (NYSE:CLGX) .

Here are highlights from Friday’s Analyst Blog:

Add These 4 Consulting Stocks to Enhance Your Portfolio

The Consulting Services industry has outpaced the S&P 500 Index so far this year.

The industry, which is placed in the top 29% of more than the 250 Zacks industries, has rallied 30.5% in the said time frame, comfortably surpassing the index’s rise of 19.7%.

This multi-billion dollar space has witnessed consistent revenue, profit and cash flow growth over the past several years.

Catalysts Benefiting the Industry

The performance of the industry is firmly tied to the condition of the broader economy, which is currently stable and expected to remain so in the rest of the year. Per the “third” estimate released by the Bureau of Economic Analysis (BEA) yesterday, GDP grew at an annualized rate of 2% in the second quarter of 2019, same as the “second” estimate released in August. The Fed expects GDP to grow 2.2% in 2019 and 2% in 2020.

Globalization, consolidation and digitization have been the key growth catalysts over the past few years. Industry players are increasingly expanding beyond the United States and Europe to other industrialized regions and growing economies. They have increased efforts to take advantage of AI, analytics, cybersecurity and digital trends.

Acquisitions and technology investments are rampant in the industry. For instance, Accenture itself has made several acquisitions to boost its consulting capabilities. The company’s recent acquisition of Parker Fitzgerald has created one of the biggest risk and regulatory consulting practices in the United Kingdom. Capgemini has combined its consulting brand with digital and creative businesses. IBM (NYSE:IBM), Deloitte, BCG and PricewaterhouseCoopers have also incorporated digital design.

4 Consulting Firms to Invest In

The industry comprises companies that offer economic, financial, business, information technology and management consulting,

With the help of the Zacks Stock Screener, we have zeroed in on four promising stocks from the consulting services industry, which have a favorable Zacks Rank #1 (Strong Buy) or 2 (Buy). These stocks have witnessed upward earnings estimate revisions in the past 60 days. You can see the complete list of today’s Zacks #1 Rank stocks here.

Huron Consulting Group Inc. is a professional services company, which provides advisory, technology and analytic solutions. It sports a Zacks Rank #1 and has a market capitalization of $1.4 billion. The company’s expected earnings growth rate for 2019 is 20.2%. The Zacks Consensus Estimate for 2019 has improved 5% in the past 60 days.

CBIZ, Inc. is a professional business services provider. It carries a Zacks Rank #2 and has a market capitalization of $1.3 billion. The company’s expected earnings growth rate for 2019 is 11.9%. The Zacks Consensus Estimate for current-year EPS has been revised 2.5% upward in the past 60 days.

CRA International, Inc. provides economic, financial, and management consulting services. The company has a Zacks Rank #2 and market capitalization of $342 million. The Zacks Consensus Estimate for 2019 EPS has been revised 1.1% upward in the past 60 days.

CoreLogic, Inc. is a provider of property information, analytics, insight and data-enabled solutions. The company has a Zacks Rank #2 and a market capitalization of $3.7 billion. The Zacks Consensus Estimate for 2019 EPS has been revised 0.8% upward in the past 60 days.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.